Company intelligence / Profile preview

Sinotek-Advocates International Industry Development

Shenzhen, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Sinotek-Advocates International Industry Development is part of a Chinese consortium that contracted Generex Biotechnology and its subsidiary NuGenerex Immuno-Oncology to develop an Ii-Key peptide-based SARS-CoV-2 vaccine candidate for human clinical trials, using Ii-Key immune system activation technology to generate viral peptides targeting the spike protein of SARS-CoV-2.[2][3][5][6][7][10][15]

Therapeutic areas: Infectious Diseases
Modalities: PeptidesVaccine
Industry: Investors

Partnerships

Generex BiotechnologyNuGenerex Immuno-OncologyChina Technology ExchangeBeijing Zhonghua Investment Fund ManagementBiology Institute of Shandong Academy of Sciences

Beyond the preview

Go deeper on Sinotek-Advocates International Industry Development.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sinotek-Advocates International Industry Development.

Explore the full profile